Pralsetinib
Pralsetinib (BLU-667) is a highly potent, selective RET inhibitor. Pralsetinib (BLU-667) inhibits WT RET, RET mutants V804L, V804M, M918T and CCDC6-RET fusion with IC50s of 0.4, 0.3, 0.4, 0.4, and 0.4 nM, respectively[1].
Product Specifications
CAS Number
2097132-94-8
Product Name Alternative
BLU-667
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
RET
Type
Reference compound
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/Blu667.html
Purity
99.98
Solubility
DMSO : ≥ 100 mg/mL
Smiles
O=C([C@@]1(OC)CC[C@H](C2=NC(NC3=NNC(C)=C3)=CC(C)=N2)CC1)N[C@H](C4=CC=C(N5N=CC(F)=C5)N=C4)C
Molecular Formula
C27H32FN9O2
Molecular Weight
533.60
Precautions
H302, H315, H319, H335
References & Citations
[1]Subbiah V, et al. Precision Targeted Therapy With BLU-667 for RET-Driven Cancers. American Association for Cancer Research. 10.1158/2159-8290.CD-18-0338.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNUB2496-500 1x 500 µL
CD44v6 (Marker of Tumor Metastasis) (CD44V6/2496), 0.2mg/mL
Sign In for Pricing
View Details 
